Fadi El Karak

760 total citations
51 papers, 462 citations indexed

About

Fadi El Karak is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Fadi El Karak has authored 51 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Fadi El Karak's work include Cancer Genomics and Diagnostics (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Renal cell carcinoma treatment (4 papers). Fadi El Karak is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Renal cell carcinoma treatment (4 papers). Fadi El Karak collaborates with scholars based in Lebanon, France and United States. Fadi El Karak's co-authors include Joseph Kattan, Marwan Ghosn, Tarek Assi, Elie Rassy, Aude Fléchon, Hampig Raphaël Kourié, Fadi Farhat, Georges Chahine, Elissar Moujaess and Fadi Nasr and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Fadi El Karak

48 papers receiving 459 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fadi El Karak Lebanon 13 225 155 78 49 46 51 462
Mark B. Ulanja United States 11 203 0.9× 96 0.6× 85 1.1× 47 1.0× 66 1.4× 43 422
Hye Jung Chang South Korea 14 275 1.2× 146 0.9× 77 1.0× 59 1.2× 52 1.1× 26 543
Jessica Weiss Canada 14 191 0.8× 172 1.1× 56 0.7× 66 1.3× 31 0.7× 55 753
Hüseyin Abalı Türkiye 16 240 1.1× 182 1.2× 126 1.6× 43 0.9× 128 2.8× 62 669
Andrew J. Klink United States 13 149 0.7× 151 1.0× 52 0.7× 32 0.7× 39 0.8× 61 524
Annelies Janssens Belgium 18 360 1.6× 333 2.1× 87 1.1× 55 1.1× 30 0.7× 62 767
Ozan Yazıcı Türkiye 14 328 1.5× 172 1.1× 105 1.3× 80 1.6× 60 1.3× 109 674
Vineet Talwar India 14 218 1.0× 213 1.4× 96 1.2× 116 2.4× 70 1.5× 95 520
Nehal Masood Pakistan 14 341 1.5× 201 1.3× 82 1.1× 23 0.5× 80 1.7× 35 617
Anya Burton United Kingdom 11 106 0.5× 61 0.4× 43 0.6× 43 0.9× 29 0.6× 22 472

Countries citing papers authored by Fadi El Karak

Since Specialization
Citations

This map shows the geographic impact of Fadi El Karak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fadi El Karak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fadi El Karak more than expected).

Fields of papers citing papers by Fadi El Karak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fadi El Karak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fadi El Karak. The network helps show where Fadi El Karak may publish in the future.

Co-authorship network of co-authors of Fadi El Karak

This figure shows the co-authorship network connecting the top 25 collaborators of Fadi El Karak. A scholar is included among the top collaborators of Fadi El Karak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fadi El Karak. Fadi El Karak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kourié, Hampig Raphaël, Lewis Nasr, Fadi El Karak, et al.. (2024). Liquid biopsy as a tool for KRAS/NRAS/BRAF baseline testing in metastatic colorectal cancer. Clinics and Research in Hepatology and Gastroenterology. 48(8). 102417–102417. 1 indexed citations
2.
Ghosn, Marwan, Joseph Kattan, Fadi El Karak, et al.. (2023). Renal cell carcinoma management: real-world practice and challenges at a national level. Future Oncology. 19(12). 863–872. 2 indexed citations
3.
Karak, Fadi El, et al.. (2023). Pharmacotherapy developments in autophagy inhibitors for bladder cancer. Expert Opinion on Pharmacotherapy. 24(17). 1853–1860. 1 indexed citations
4.
Assi, Hazem, et al.. (2023). Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC). Oncotarget. 14(1). 517–525. 4 indexed citations
5.
6.
7.
Ayoub, Georges, Hampig Raphaël Kourié, Joseph Kattan, et al.. (2023). Genetic Markers of Chronic Lymphocytic Leukemia: A Retrospective Study of 312 Patients from a Reference Center in Lebanon. Future Oncology. 19(29). 1979–1990. 4 indexed citations
8.
Macaron, Walid, et al.. (2022). Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. Current Problems in Cancer. 46(3). 100859–100859. 9 indexed citations
9.
10.
Ibrahim, Tony, Elie Rassy, Fadi El Karak, et al.. (2020). Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice. Bulletin du Cancer. 107(4). 410–416.
11.
Zerdan, Maroun Bou, et al.. (2020). Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region. Cancer Treatment and Research Communications. 26. 100275–100275. 3 indexed citations
12.
Rassy, Elie, Marwan Ghosn, Fadi Farhat, et al.. (2018). Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. Breast Care. 13(2). 119–123. 2 indexed citations
13.
Assi, Tarek, Joseph Kattan, Elie Rassy, et al.. (2018). Efficacy and safety of everolimus in hormone receptor positive breast cancer in a developing country: Real-life single institutional experience. Journal of Cancer Research and Therapeutics. 14(5). 1112–1116. 2 indexed citations
14.
Assi, Tarek, Elie Rassy, Tony Ibrahim, et al.. (2016). The role of palliative care in the last month of life in elderly cancer patients. Supportive Care in Cancer. 25(2). 599–605. 6 indexed citations
15.
Rassy, Elie, et al.. (2016). Onconephrology: What Should the Internist Know About Targeted Therapy in Solid Tumors?. PubMed. 10(4). 169–75. 3 indexed citations
16.
Assi, Tarek, Elie Rassy, Samer Tabchi, et al.. (2015). Treatment of cancer patients in their last month of life: aimless chemotherapy. Supportive Care in Cancer. 24(4). 1603–1608. 24 indexed citations
17.
Karak, Fadi El, et al.. (2015). BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.. PubMed. 8(3). 3294–8. 2 indexed citations
18.
Tabchi, Samer, Elie Rassy, Fadi El Karak, et al.. (2015). Validation of the EORTC QLQ-INFO 25 questionnaire in Lebanese cancer patients: Is ignorance a Bliss?. Quality of Life Research. 25(6). 1597–1604. 12 indexed citations
19.
Ghosn, Marwan, Carla Hajj, Joseph Kattan, et al.. (2011). Triple-Negative Breast Cancer in Lebanon: A Case Series. The Oncologist. 16(11). 1552–1556. 10 indexed citations
20.
Heudel, Pierre-Étienne, Fadi El Karak, Nabil Ismaili, Jean‐Pierre Droz, & Aude Fléchon. (2009). Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experience. BMC Urology. 9(1). 5–5. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark B. Ulanja Breakdown of academic impact, for papers by Hye Jung Chang Breakdown of academic impact, for papers by Jessica Weiss Breakdown of academic impact, for papers by Hüseyin Abalı Breakdown of academic impact, for papers by Andrew J. Klink Breakdown of academic impact, for papers by Annelies Janssens Breakdown of academic impact, for papers by Ozan Yazıcı Breakdown of academic impact, for papers by Vineet Talwar Breakdown of academic impact, for papers by Nehal Masood Breakdown of academic impact, for papers by Anya Burton
Rankless by CCL
2026